Variable | Paediatric and AYA 74.4% | Reference (27) | Variable | Adults 25.6% | Reference (27) | |||
Grouping (%) | HR | IR | SR | [18] | Grouping (%) | SR | HR | [3] |
 | 21.4 | 29.1 | 49.5 |  |  | 32.1 | 67.9 |  |
Age (years) | 5 | 5 | 5 | [18] | Age (years) | 31 | 53 | [1] |
Body surface (m2) | 0.75 | 0.75 | 0.75 | RCPCH | Body surface (m2) | 1.79 | 1.79 | [33] |
 |  |  |  |  | Eligible for transplant (%) | 47 | 47 | [34] |
Health utilities decrements (%) | Â | Â | Â | Assumption (decrement from [28]) | Health utilities decrements (%) | Â | Â | Assumption (decrement from [28]) |
 Ind | 25 | 25 | 25 |  |  Ind | 25 | 25 |  |
 C | 16 | 16 | 16 |  |  Int | 25 | 25 |  |
 IM1 | 12 | 12 | 12 |  |  C1 | 12 | 12 |  |
 DI1 | 12 | 12 | 12 |  |  C3 | 12 | 12 |  |
 IM2 | 12 | 12 | 12 |  |  M | 7 | 7 |  |
 DI2 | 12 | 12 | 12 |  |  |  |  |  |
 CT | 7 | 7 | 7 |  |  |  |  |  |
Hypersensitivity risk (%) | Hypersensitivity risk (%) | |||||||
 Pegaspargase |  Pegaspargase | |||||||
  first line (Ind) | 2 | 2 | 2 | [18] |   first line (Ind/Int) | 2 | 2 | Assumption |
  second line (DI/C) | 2 | 2 | 2 | [18] |   second line (Int) | 2 | 2 | Assumption |
 native asparaginase |  native asparaginase | |||||||
  first line (Ind) | 20 | 20 | 20 | [29] |   first line (Ind) | 20 | 20 | Assumption |
  second line (DI/C) | 20 | 20 | 20 | Assumption |   second line (Int) | 20 | 20 | Assumption |
 Erwinia asparaginase |  Erwinia asparaginase | |||||||
  second line (DI/C) | 37 | 37 | 37 | [30] |   second line (Int) | 37 | 37 | Assumption |
 Impact |  Impact | |||||||
  Utility decrement | 0.014 | 0.014 | 0.014 | [31] |   Utility decrement | 0.014 | 0.014 | [31] |
  Cost (£) | 470 | 470 | 470 | [32] |   Cost (£) | 470 | 470 | [32] |
5-year outcomes | 5-year outcomes | |||||||
 Asparaginase completed |  Asparaginase completed | |||||||
  OS (%) | 95 | 90 | 80 | Assumption from [18] |   OS (%) | 40 | 30 | [3] |
  EFS (%) | 90 | 85 | 75 |  |   EFS (%) | – | – | Assumption |
 Asparaginase discontinued |  Asparaginase discontinued |  |  | EFS=OS | ||||
  RR for OS | 0.95 | 0.95 | 0.95 | Assumption | RR for OS | 0.95 | 0.95 | Assumption |
  RR for EFS | 0.95 | 0.95 | 0.95 | Assumption | RR for EFS | – | – | Assumption |
 | EFS=OS | |||||||
Impact of R/STa | ||||||||
 Utility decrement (%)b | 20 | 20 | 20 | Assumption |  |  |  |  |
 Increased mortality (%)c | 90 | 90 | 90 | Assumption |  |  |  |  |